Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
US Army
Covington
UBS
Federal Trade Commission
Mallinckrodt
McKesson
Medtronic
Boehringer Ingelheim

Generated: May 22, 2018

DrugPatentWatch Database Preview

EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Efidac 24 Pseudoephedrine Hydrochloride/brompheniramine Maleate, and when can generic versions of Efidac 24 Pseudoephedrine Hydrochloride/brompheniramine Maleate launch?

Efidac 24 Pseudoephedrine Hydrochloride/brompheniramine Maleate is a drug marketed by Alza and is included in one NDA.

The generic ingredient in EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE is brompheniramine maleate; pseudoephedrine hydrochloride. There are twenty-one drug master file entries for this compound. Additional details are available on the brompheniramine maleate; pseudoephedrine hydrochloride profile page.
Summary for EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE
Drug patent expirations by year for EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE

US Patents and Regulatory Information for EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alza EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE brompheniramine maleate; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 019672-001 Mar 29, 1996 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alza EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE brompheniramine maleate; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 019672-001 Mar 29, 1996 ➤ Sign Up ➤ Sign Up
Alza EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE brompheniramine maleate; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 019672-001 Mar 29, 1996 ➤ Sign Up ➤ Sign Up
Alza EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE brompheniramine maleate; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 019672-001 Mar 29, 1996 ➤ Sign Up ➤ Sign Up
Alza EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE brompheniramine maleate; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 019672-001 Mar 29, 1996 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Argus Health
AstraZeneca
Cantor Fitzgerald
QuintilesIMS
Fish and Richardson
McKesson
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.